Vaccine to prevent pancreatic, colorectal cancer relapse yields ‘exciting’ early results

Results of a phase 1 trial for a vaccine targeting micrometastatic disease markers in patients already treated for pancreatic or colorectal cancer showed potential in preventing recurrence, according to a study in Nature Medicine.
Among the trial cohort, 84% of patients had a positive T-cell response, and those who hit or exceeded the median rate did not reach their median recurrence-free survival. No patients had grade 3 or higher adverse events.
“We see a lot of negative trials [in pancreatic cancer],” Shubham Pant, MD, MBBS, a professor in the department of gastrointestinal

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart